Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Company News
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Events
Directory
Editorial team
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Home
C-squared Pharma
C-squared Pharma
Activities:
Ingredients
Trending Articles
Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings
The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end...
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes
The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming...
Medicines Discovery Catapult and Astral Systems secure £1.54m to develop the UK’s radiopharmaceutical lab of the future
Funding will help lay the foundations to make UK radiopharmaceutical production faster, more consistent and ready for rising demand
Bio-Rad expands precision oncology research portfolio for advanced molecular analysis workflows
Expanded portfolio Includes new droplet digital PCR assays, Reagents and technologies to support oncology research applications and extend the capabilities of the QX700 ddPCR...
You need to be a subscriber to read this article.
Click here
to find out more.
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep...
Related Content
Ingredients
C2 Pharma launches brinzolamide ophthalmic API
C2 Pharma has added brinzolamide to its ophthalmic API portfolio following completion of process validation and submission of a US Drug Master File
Manufacturing
C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride
C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing
C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs
The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients
C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch
C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory
C2 Pharma's Tropicamide receives CEP from the European Directorate
The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients
C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API
C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients
C2 Pharma to participate in DCAT Week 2024
The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Subscribe now